Vol V, Issue 3 Date of Publication: July 29, 2020
DOI: https://doi.org/10.20529/IJME.2020.068

Views
, PDF Downloads:

Hydroxychloroquine and Remdesivir in COVID-19: A critical analysis of recent events

Amit Dang
BN Vallish
Sumit Dang
Abstract:
The world is going through an unprecedented medical emergency with no effective remedy for the SARS-CoV2 virus causing Covid-19. Two drugs used for other indications in the past, hydroxychloroquine (HCQ) and remdesivir (RDV), are sought to be repurposed to treat Covid-19. Both these drugs have received emergency use authorisation by the US Food and Drug Administration. In this review, we critically analyse the identification of and subsequent events concerning these two drugs as potential treatment options for Covid-19, and conclude by raising some ethical issues that require serious thought from the global scientific community concerned with using these two drugs against Covid-19.

Key Words: Covid-19, hydroxychloroquine, remdesivir, USFDA, emergency use authorisation


Copyright and license
©Indian Journal of Medical Ethics 2020: Open Access and Distributed under the Creative Commons license ( CC BY-NC-ND 4.0),
which permits only non-commercial and non-modified sharing in any medium, provided the original author(s) and source are credited.

Full Text

HTML | PDF
Help IJME keep its content free. You can support us from as little as Rs. 500 Make a Donation